Monday, June 1, 2009

THE FUTURE OF AUTOMOTIVE PRODUCT LIABILITY

THE FUTURE OF AUTOMOTIVE PRODUCT LIABILITY CLAIMS FOLLOWING AUTOMOTIVE BANKRUPTCY

GM and Chrysler have both now filed for bankruptcy, and the future of pending civil claims involving many injured individuals as a result of defective products (seat belts, roofs, gas tanks, air bags, etc.) is looking ominous.

As a product liability lawyer, I have had the honor of representing individuals, including children, who have been permanently injured due to manufacturing negligence. Currently, The Lyon Firm is active in automotive product liability and is representing a nineteen year old women from Shelby Ohio who was paralyzed due to a defective lap belt and seat design in a Pontiac Grand Am. At the time of the accident, she was a passenger in the middle rear seat when the car sustained a head on collision with a tree. During the impact, she sustained injuries to her lower lumbar and abdomen. The injuries have left her without any bladder control and partial paralysis in her lower extremities. She will never walk without assistance again and will need ongoing medical care. GM was well aware of the defective lap belt and defective seat for decades prior to manufacturing the 2000 Grand Am in which my client was riding.
Now, due to additional neglect in the company, it appears that many personal injury victims who sustained injuries and death from automotive defects in GM and Chrysler vehicles will go uncompensated. The effect of these bankruptcies will place an additional burden on the tax payer to provide medical care and assistance to these individuals and leaving the individuals grossly undercompensated for the injuries they sustained through no fault of their own.

THE STAY OF AUTOMOTIVE PRODUCT LIABILITY CLAIMS

At this time, the details of a product liability fund or appropriate course of litigation has not been announced but it is anticipated that there will be little recourse for these individuals. Currently, it is reasonable to assume the hundreds of automotive crashworthiness lawsuits being actively litigated across the country will be stayed pursuant to an automatic stay under Section 362 of the Bankruptcy Code.

The stay will likely include all claims that have been filed or could have been filed to recover any claim that arose prior to the commencement of the bankruptcy. [11 U.S.C. § 362(a)(1) (1993). If a stay is put into effect, it will likely cause all pending litigation to stop and may also prevent new cases from being filed until the bankruptcy court determines the stay should be lifted.

RELIEF FROM AUTOMOTIVE BANKRUPTCY FOR AUTOMOTIVE PRODUCT LIABILITY CLAIMS.

A court may grant relief from such a stay to allow a party to proceed under certain limited circumstances.
1. Relief would result in a partial or complete resolution of the issues;
2. There is a lack of any connection with or interference with the bankruptcy case;
3. The other proceeding involves the debtor as a fiduciary;
4. A specialized tribunal with the necessary expertise has been established to hear the cause of action;
5. The debtor's insurer has assumed ful responsibility for defending it;
6. The action primarily involves third parties;
7. The litigation in another forum would prejudice the interests of other creditors;
8. The judgment claim arising from the other action is subject to equitable subordination;
9. The moving party's success in the other proceeding would result in a judicial lien avoidable by the debtor;
10. The interests of judicial economy and the expeditious and economical resolution of litigation;
11. The parties are ready for trial in the other proceeding; and
12. The impact of the stay on the parties and the balance of the harms.

Bankruptcy Stay Authority: See, In re Mid-Atlantic Handling Sys., LL C, 304 B.R. at 130 (citing In re Ice Cream Liquidation, Inc., 281 B .R. 154, 165 (Bankr.D.Conn.2002)). See also In re Curtis, 40 B.R. 795, 799-800 (Bankr.D.Utah 1984) (utilizing same factors). All twelve factors are not necessarily present in a particular case, and a court need not rely on any plurality of factors in deciding whether to lift the automatic stay. In re Mid-Atlantic Handling Sys., LLC, 304 B.R. at 130 (citing In re Ice Cream Liquidation, Inc., 281 B.R. at 165).

AUTOMOTIVE PRODUCT LIABILITY CLAIMS ARE UNSECURED CREDITORS

In the rare event of removing the Stay, the future looks very difficult due to the classification as an un-secured creditor -- , i.e., the lowest level of priority in a very large pool of creditors. As a result, “The most likely result is they are going to get chewed up and get little if anything,” said Richard A. Zitrin, who teaches legal ethics at the Hastings College of the Law of the University of California in San Francisco. “They’re being put in a bucket with much more powerful forces, so they are going to be the low people in the pecking order.”

OPTIONS FOR PROTECTING AUTOMOTIVE PRODUCT LIABILITY CLAIMS IN BANKRUPTCY

There has been very little open discussion on the best manner to protect the pending and future product liability claims. However, this is a big issue not only for the injured but for any company that is going to be purchasing GM or Chrysler assets. It is in the future of liabilities that there has likely been more discussion, as any buyer will be concerned with assuming the past and future liabilities.

One way to protect all consumers would be for the bankruptcy court to require the new Chrysler to either set aside money to cover claims or require a special insurance policy, said Norman I. Silber, a law professor at Hofstra University, who specializes in consumer law. This would also protect a future buyer. This approach would work well for GM as well. The government should not overlook the product liability issues without coming to some solution. As mentioned above, the government will be stuck with the health bills, so they should require these companies to set up a system for taking responsibility for its past decisions. Unfortunately, these companies are the worst kind of offenders -- they hurt so many people and they cannot pay for the damage.

Tuesday, May 5, 2009

HYDROXYCUT RECALL FOR LIVER DAMAGE

In a long legacy of recalls, which has included some of the worst mass torts in history, most notably phen fen, the diet industry has again shown its inability to monitor itself and provide a safe and effective product to consumers. Last week, Iovate in cooperation with the FDA issued a recall for numerous hydroxycut products, which are not believed to be connected to liver damage in consumers nationwide. Following the review of reported adverse events produced by the manufacturer, as well as reports in peer reviewed medical journals, the FDA concluded that hydroxycut products present a real risk of injury which includes liver damage and rhabdomyolisis (a condition that can lead to kidney failure).

The Lyon Firm is evaluating cases involving the following products: If you have taken these products and have suffered an injury, please call for a free consultation. Please also secure the bottle in a safe place and gather any medical records in your possession. These will be necessary for the review process.


HYDROXYCUT RAPID RELEASE REGULAR CAPLETS
631656893649 Hydroxycut 140ct Cap US631656833621 Hydroxycut 60 GNC US631656600988 Hydroxycut 300ct Caplets US631656890129 Hydroxycut 36ct Cap US "with CARDS"631656282245 Hydroxycut 160ct Cap US *Discontinued*631656873214 Hydroxycut 58ct Cap US631656813418 Hydroxycut 70ct Cap US631656808612 Hydroxycut 70ct Caps US *Discontinued*631656808117 Hydroxycut 100 cap US *Discontinued*631656818642 Hydroxycut 140ct Cap US *Discontinued*631656882414 Hydroxycut 80ct Caps US *Discontinued*631656843262 Hydroxycut 210ct Cap US631656828665 Hydroxycut 210 cap US *Discontinued*631656600582 Hydroxycut 60ct + 1 Hydroxycut Sachet WB US631656600476 Hydroxycut 72ct + Hydroxycut Sachet WB US631656600483 Hydroxycut 100ct Caplets US631656600506 Hydroxycut 150ct Caplets US631656601251 Hydroxycut 170 Caplets US631656600452 Hydroxycut 30ct Caplets US


HYDROXYCUT HARDCORE LIQUID CAPSULES
631656600650 Hydroxycut Hardcore 120ct US631656600834 Hydroxycut Hardcore 210ct US631656001778 Hydroxycut Hardcore 30ct US631656601435 Hydroxycut Hardcore 252ct US631656601848 Hydroxycut Hardcore 30ct US Trial - Bodybuilding.com631656601749 Hydroxycut Hardcore 120ct US NEW631656601763 Hydroxycut Hardcore 252ct US631656601756 Hydroxycut Hardcore 210ct US NEW
HYDROXYCUT CAFFEINE-FREE CAPLETS
631656801224 Hydroxycut Caffeine Free 140ct Cap US631656821246 Hydroxycut Caffeine Free 330ct Cap US631656801217 Hydroxycut Caffeine Free 100ct Cap US631656801231 Hydroxycut Caffeine Free 58ct Cap US631656899122 Hydroxycut Caffeine Free 36ct Cap US631656600544 Hydroxycut Caffeine Free 60ct US631656600551 Hydroxycut Caffeine Free 72ct US631656600568 Hydroxycut Caffeine Free 100ct US


HYDROXYCUT MAX CAPLETS
631656601466 Hydroxycut Max 120ct bonus + 1Hyd Max Sachet WB US631656601633 Hydroxycut Max 210ct Bonus + 1 Hyd Max Sachet WB US


HYDROXYCREGULAR DRINK PACKET
631656860191 Hydroxycut Weight Loss Drink Mix 21pk Sachet - Wild Berry US631656860313 Hydroxycut Weight Loss Drink Mix 21pk Sachet - Country Lemonade US


HYDROXYCUT HARDCORE DRINK PACKET (IGNITION STIX)
631656701326 Hydroxycut Hardcore Drink Mix 2.7g Sachet - Blue Raspberry US631656701319 Hydroxycut Hardcore Drink Mix 2.6g Sachet - Fruit Punch US631656760118 Hydroxycut Hardcore Drink Mix 40pk x 2g Sachet - Fruit Punch US631656760125 Hydroxycut Hardcore Drink Mix 40pk x 2g Sachet - Blue Raspberry US


HYDROXYCUT CAFFEINE-FREE DRINK PACKET
631656760095 Hydroxycut Caffeine Free Drink Mix 21pk x 3.6g Sachet - Raspberry Ice US


HYDROXYCUT MAX DRINK PACKET
631656860375 Hydroxycut Max Drink Mix 40pk x 2.4g Sachet - Wild Berry US631656860382 Hydroxycut Max Drink Mix 40pk x 2.7g Sachet - Lemonade US


HYDROXYCUT LIQUID SHOT
631656800159 Hydroxycut Weight Loss Single Shot 2oz - Wild Berry US631656860207 Hydroxycut Weight Loss Shot 2 x 2oz Pk - Wild Berry US631656860498 Hydroxycut Instant Weight Loss Shot 12 x 2oz - Wild berry US


HYDROXYCUT MAX AQUA SHED
631656601855 Hydroxycut Max Aqua Shed 60ct Capsules US


HYDROXYCUT HARDCORE RTD
631656860436 Hydroxycut Hardcore 4 x8oz RTD - Grape Infusion US631656860399 Hydroxycut Hardcore 4 x 8oz RTD - Triple WildBerry US631656860665 Hydroxycut Hardcore 12-pack RTD - Grape Infusion US631656860467 Hydroxycut Hardcore 3 x 4-pack RTD - Grape Infusion US631656860443 Hydroxycut Hardcore 3 x 4-pack RTD - Triple Wildberry US631656860443 Hydroxycut Hardcore 3 x 4-pack RTD - Triple Wildberry US631656860568 Hydroxycut Hardcore 12-pack RTD - Triple Wildberry US


HYDROXYCUT 24
631656600933 Hydroxycut 24 (96 caps/ blister pack) US


HYDROXYCUT CARB CONTROL
631656800036 Hydroxycut Carb Control 58ct Cap US631656800029 Hydroxycut Carb Control 100ct Cap US631656800012 Hydroxycut Carb Control 140ct Cap US


HYDROXYCUT NATURAL
631656600889 Hydroxycut Natural 100ct US

Please note that Hydroxycut Hoodia and Hydroxycut Cleanse products are not included in this recall; nor are any other Iovate products.

Thursday, April 30, 2009

Mako 282 Defects

NATIONAL CLASS ACTION REMAINS PENDING FOR MAKO 282 and 28

A National Class Action remains pending in the Southern District of Florida related to the design issues affecting Mako 282 and Mako 28 offshore fishing vessels. The Lyon Firm is working with Peterson and Associates on behalf of Mako 282 owners who have experienced structural cracks in the hull. The Coast Guard found in 2004 that these boats have structural problems that may result in hull cracking and failure. Three class representatives are named in the case on behalf of 216 boat owners. If you would like more information about the case, please contact Joseph Lyon.

Wednesday, April 15, 2009

EXPANDING THE MEDICAL MARKET BY EXPANDING THE STANDARD OF CARE FOR THE USE OF ANGIOPLASTY AND CORONARY STENTS


Modern medicine is big business. Cardiology is a 100 Billion dollar a year industry. As any business, the medical providers need new markets to grow the business. Consequently, physicians and hospitals promote and recommend surgeries that have little or no basis in science or have been proven to provide little medical benefit over more conservative approaches. The most common area of surgical abuse is in the area of interventional cardiology and the use of angioplasty and coronary stents.


A. UNNECESSARY CORONARY STENT PLACEMENT


The American College of Cardiology Guidelines require that a patient demonstrate objective evidence of ischemia prior to intervention. Furthermore, the FDA has only approved drug eluting stents to treat coronary artery disease where the lesion has been identified to be flow restrictive. However, many physicians routinely place drug eluting stents and older metal stents in coronary arteries for prophylactic purposes -- that is, to prevent the further development of coronary artery disease. Despite this common practice, there is no study to show that placing a stent is effective at slowing the progression of coronary disease. On the other hand, numerous studies have demonstrated success with medication in slowing the progression of coronary artery disease. Indeed there is no evidence that a stent is more effective than medication at preventing a future myocardial infarction than medication for patients with "stable angina".


Despite this evidence, many patients undergo angioplasty and stenting with minor chest pain and no evidence of ischemia. To justify the use of a stent, when questioned, a cardiologist will attempt to expand the definition of" stable angina" or allude to the procedure as art and science and filled with judgment. Both explanations are misrepresentations of the state of the art of medicine, and appear to be attempts to expand the potential pool of patience who qualify for the procedure.


One of the primary defenses in any medical malpractice action is the physician judgment. The defense uses this magical card to explain why a physician would take a certain action despite a lack of scientific data to support the action. Essentially, the defense focuses on the gray areas of medicine where there is no right or wrong answer. The theme that medicine is not an exact science is played and the physcian judgment defense fits perfectly to explain that physicians must make difficult decisions in light of little scientific data. In the context of interventional cardiology, with patients with stable angina and no evidence of ischemia, there is no judgment - the standard of care remains that medication should be used as opposed to a stent, because the risk of stent thrombosis and death outweighs any benefit of the stent.


Incredibly, when faced with a patient with moderate or non-significant disease, Physicians often will not discuss the available options with medication or the clinical trials that show that medication is as beneficial as intervention. The failure to discuss treatment options is a breach of informed consent. If you or a family member suffered an adverse event following the placement of a drug eluting stent, catheterization, or, angioplasty, please contact Mr. Lyon through the contact form at http://www.thelyonfirm.com/.

Tuesday, January 27, 2009

New FDA Warning on Dietary Supplement HYPERDRIVE 3.0

The FDA issued warning on a dietary supplement HYPERDRIVE 3.0 due to the presence on a controlled substance, sibutramine. Dietary supplements are not reviewed by the FDA pre-market. The lack of oversight presents the safety hazard of products reaching the market with dangerous ingredients such as sibutramine.

The dietary supplement industry has a terrible history, including phen-fen and ephedra products that injured thousands of consumer. Despite the lack of oversight, and history of problems, the products remain very popular and often present unknown health risks to consumers.


Until the FDA takes an active, pre-market, approach, the public will continue to be exposed to dangerous dietary supplements.

Reducing Medical Errors with Electronic Medical Records

The Obama administration has prioritized funding allocated for electronic medical records. This approach is in line with the CBO's report on medical errors resulting from poor communication within the field. Despite the common sense approach and clear benefit to health care providers and patients, some medical groups are resisting the movement towards electronic medical records claiming the cost with not outweigh the benefit. This argument appears to be based in risk management policies and attempts to limit the available evidence to evaluate and criticize medical care.

The electronic medical records will allow physicians to share information in a more timely fashion, allow emergency room physicians real time access to a patient's history, and further reduce mistakes with handwriting and records routing. In my experience evaluating medical malpractice cases, many injuries would have been avoided had the physician had the information at the appropriate time. Many mistakes arise from test results not being communicated to a family physician or an emergency room physician being unaware of a patient's history. One of the most common mistakes are medication errors, which can be readily reduced through electronic medical records and software.